Author Index to Volume 53

Abraham K. *See* Davidson JRT
Addington A. *See* Nestadt G
Adès J. *See* Gorwood P
Adleman N. *See* Chang K
Adler L. *See* Michelson D
Allen AJ. *See* Michelson D
Alpert NM. *See* Weiss AP
Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression, 691
Amaro E. *See* Mataix-Cols D
Andrew C. *See* Mataix-Cols D
Angold A. *See* Silberg JL
Anisman H. *See* Tannenbaum B
Apergis J. *See* Sullivan GM
Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenic patients, 56
Åsberg M. *See* Jönsson EG
Asbjørnsen A. *See* Hugdahl K

Bacanu S-A. *See* Williamson DE
Badner JA. *See* Schulze TG
Baghai TC. *See* Bondy B
Baker CK. *See* Norris FH
Bär T. *See* Senkowski D
Barber J. *See* McCaddon A
Barch DM, Sheline YI, Csernansky JG, Snyder AZ. Working memory and prefrontal cortex dysfunction: Specificity to schizophrenia compared with major depression, 376
Barnea-Goraly N. *See* Chang K
Barnett S. *See* Davidson JRT
Barreira PJ. *See* Henry ME
Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. Dysregulated brain development in adult men with schizophrenia: A magnetic resonance imaging study, 412
Batel P. *See* Gorwood P
Bauer M. *See* Gyulai L; Sachs GS
Beasley C. *See* Chana G
Beaudoin G. *See* Lévesque J
Beauregard M. *See* Lévesque J
Begni S, Moraschi S, Bignotti S, Fumagalli F, Rillosi L, Perez J, Gennarelli M. Association between the G1001C polymorphism in the *GRIN1* gene promoter region and schizophrenia, 617
Beiderman J. *See* Braaten EB
Bennett C. *See* Arvindakshan M
Bertolino A, Frye M, Callicott JH, Mattay VS, Rakow R, Shelton-Repella J, Post R, Weinberger DR. Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging, 906
Beveridge A. *See* Warwick MM
Biederman J. *See* Hirshfeld-Becker DR; Mick E; Wozniak J
Biederman J, Mick E, Wozniak J, Monuteaux MC, Galdo M, Faraone SV. Can a subtype of conduct disorder linked to bipolar disorder be identified? Integration of findings from the Massachusetts General Hospital Pediatric Psychopharmacology Research Project, 952
Biederman J. Pediatric bipolar disorder coming of age, 931 (editorial)
Bienvenu OJ. *See* Nestadt G
Bignotti S. *See* Begni S
Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression?, 193
Bodie B. *See* Herman JP
Boksman K. *See* Lanius RA
Bondy B, Baghai TC, Minov C, Schüle C, Schwarz MJ, Zwanzger P, Rupprecht R, Möller H-J. Substance P serum levels are increased in major depression: Preliminary results, 538
Boni C. *See* Gorwood P
Born C. *See* Frodl T
Boronow J. *See* Hibbeln JR
Bottlender R. *See* Frodl T
Bourgouin P. *See* Lévesque J
Boutros NN. *See* Grunwald T
Bowden C. *See* Sachs GS
Braaten EB, Beiderman J, Monuteaux MC, Mick E, Calhoun E, Cattan G, Faraone SV. Revisiting the association between attention-deficit/hyperactivity disorder and anxiety disorders: A familial risk analysis, 93
Bradbury R. *See* Dean B
Braff DL. *See* Green MF; Paulus MP
Brammer MJ. *See* Lange K; Mataix-Cols D
Breitenstein C. *See* Knecht S
Breitmeyer B. *See* Green MF
Bremner JD, Vythilingam M, Vermetten E, Southwick SM, McGlashan T, Staib LH, Soufer R, Charney DS. Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse, 879
Breunis MN, Kupka RW, Nolen WA, Suppes T, Denicoff KD, Leverich GS, Post RM, Drexhage HA. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder, 157
Britton C. *See* Phan KL
Brown GG. *See* Paulus MP
Bryant RA. Early predictors of posttraumatic stress disorder, 789
Buitron C. *See* Hof PR
Bullmore ET. *See* Lange K
Bunney WE Jr. *See* Molnar M
Butterfield MI. *See* Davidson JRT
Byne W. *See* Hof PR

Calabrese J. *See* Sachs GS
Calhoun E. *See* Braaten EB
Callicott JH. *See* Bertolino A
Calltharp S. *See* Hirshfeld-Becker DR
Cameron JL. *See* Williamson DE
Cannon TD. *See* Glahn DC
Carlson GA, Youngstrom EA. Clinical implications of pervasive manic symptoms in children, 1050
Carpenter WT, Gold JM. Atypical antipsychotic drugs improve

© 2003 Society of Biological Psychiatry

0006-3223/03/$30.00
doi:10.1016/S0006-3223(03)00503-1

cognition in schizophrenia, 265–corr (reply)
Carrey N. *See* MacMaster FP
Carroll RJ. *See* Mallinckrodt CH
Carter CS. *See* Perlstein WM
Casat CD. *See* Davidson JRT
Casey BJ. *See* Durston S
Cattan G. *See* Braaten EB
Celano E, Tiraboschi E, Consogno E, D'Urso G, Mbakop MP, Gennarelli M, de Bartolomeis A, Racagni G, Popoli M. Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs, 442
Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: Evidence for decreased neuronal somal size and increased neuronal density, 1086
Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. Decreased N-acetylaspartate in children with familial bipolar disorder, 1059
Chang K, Steiner H, Dienes K, Adleman N, Ketter T. Bipolar offspring: A window into bipolar disorder evolution, 945
Chao HM. *See* Richardson MA
Charney DS. *See* Bremner JD; Friedman MJ; Kupfer DJ; Leibenluft E; Manji HK
Chen B, Wang J-F, Sun X, Young LT. Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells, 530
Chen Y-S. *See* Schulze TG
Cicchetti D. *See* Tsatsanis KD
Cichon S. *See* Jönsson EG
Clark CR, McFarlane AC, Morris P, Weber DL, Sonkkilla C, Shaw M, Marcina J, Tochon-Danguy HJ, Egan GF. Cerebral function in posttraumatic stress disorder during verbal working memory updating: A positron emission tomography study, 474
Clark DM. *See* Ehlers A
Clelland JD. *See* Richardson MA
Cnaan A. *See* Gyulai L
Cohen BM. *See* Henry ME
Cohen H, Zohar J, Matar M. The relevance of differential response to trauma in an animal model of posttraumatic stress disorder, 463
Cohen JA. Treating acute posttraumatic reactions in children and adolescents, 827
Cohen JD. *See* Perlstein WM
Coleman K. *See* Williamson DE
Connor KM. *See* Davidson JRT
Consogno E. *See* Celano E
Copolov DL. *See* Dean B
Cotter D. *See* Chana G
Csernansky JG. *See* Barch DM
Cullen B. *See* Nestadt G
Cullen S. *See* Mataix-Cols D

Dannon PN. *See* Grunhaus L
Davidson JRT, Abraham K, Connor KM, McLeod MN. Effectiveness of chromium in atypical depression: A placebo-controlled trial, 261
Davidson JRT, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S. Mirtazapine versusplacebo in posttraumatic stress disorder: A pilot trial, 188
Davidson MC. *See* Durston S
Davidson T. *See* Quintana J
Davies G. *See* McCaddon A
Davis CL. *See* Frye MA
Davis KL. *See* Hof PR
Daws LC. *See* Overstreet DH
de Bartolomeis A. *See* Celano E
Dean B, Bradbury R, Copolov DL. Cannabis-sensitive dopaminergic markers in postmortem central nervous system: Changes in schizophrenia, 585
DeBrota DJ. *See* Mallinckrodt CH
Debsikdar V. *See* Arvindakshan M
Decker LR. *See* Phan KL
Delrahim KK. *See* Wang X-F
Denicoff KD. *See* Breunis MN; Manji HK
Densmore M. *See* Lanius RA
DePaulo JR Jr. *See* Schulze TG
Devlin BJ. *See* Williamson DE
Dickerson F. *See* Hibbeln JR
Dienes K. *See* Chang K
Dietrich A. *See* Michelson D
Dixit NK. *See* Perlstein WM
Dolbert OT. *See* Grunhaus L
Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients, 1143
Dolnak D. *See* Wang X-F
Doty RL. *See* Turetsky BI
Drexhage HA. *See* Breunis MN
Dubé S. *See* Mallinckrodt CH; Rush AJ
D'Urso G. *See* Celano E
Durston S, Tottenham NT, Thomas KM, Davidson MC, Eigsti I-M, Yang Y, Ulug AM, Casey BJ. Differential patterns of striatal activation in young children with and without ADHD, 871

Eaves LJ. *See* Silberg JL
Edwards E. *See* Kohen R
Egan GF. *See* Clark CR
Egeland J. *See* Hugdahl K
Ehlers A, Clark DM. Early psychological interventions for adult survivors of trauma: A review, 817
Eigsti I-M. *See* Durston S
Elger CE. *See* Grunwald T
Ellger T. *See* Knecht S
Eugène F. *See* Lévesque J
Evans D. *See* Arvindakshan M
Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, Jeste DV. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients, 422
Everall IP. *See* Chana G

Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression?, 640
Falkai P. *See* Smith GN
Faraone SV. *See* Biederman J; Braaten EB; Hirshfeld-Becker DR; Mick E; Wozniak J
Faraone SV, Glatt SJ, Tsuang MT. The genetics of pediatric-onset bipolar disorder, 970
Farde L. *See* Jönsson EG
Fava M. *See* Sachs GS
Fava M. Diagnosis and definition of treatment-resistant depression, 649
Fenton WS. *See* Hibbeln JR
Fera F. *See* Hariri AR
Fernández G. *See* Grunwald T
Fischman AJ. *See* Weiss AP
Foa EB. *See* Friedman MJ
Forslund K. *See* Jönsson EG
Frangou S. *See* Schulze K
Frank E. *See* Grote NK; Sachs GS
Frank L. *See* Paulus MP
Friedman E. *See* Overstreet DH

Friedman MJ, Foa EB, Charney DS. Toward evidence-based early interventions for acutely traumatized adults and children, 765 (editorial)
Friedrich VL Jr. *See* Hof PR
Fristad MA, Gavazzi SM, Mackinaw-Koons B. Family psychoeducation: An adjunctive intervention for children with bipolar disorder, 1000
Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jäger M, Groll C, Bottlender R, Leinsinger G, Möller H-J. Large amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects, 338
Frye MA. *See* Altshuler LL; Bertolino A
Frye MA, Pazzaglia PJ, George MS, Luckenbaugh DA, Vanderham E, Davis CL, Rubinow DR, Post RM. Low CSF somatostatin associated with response to nimodipine in patients with affective illness, 180
Fumagalli F. *See* Begni S

Galderisi S, Mucci A, Monteleone P, Sorrentino D, Piegari G, Maj M. Neurocognitive functioning in subjects with eating disorders: The influence of neuroactive steroids, 921
Galdo M. *See* Biederman J
Galliant J. *See* Senkowski D
Gambarana C. *See* Grappi S
García-Espana F. *See* Gyulai L
Gati JS. *See* Lanius RA
Gavazzi SM. *See* Fristad MA
Gebarski SS. *See* Starkman MN
Gennarelli M. *See* Begni S; Celano E
George MS. *See* Frye MA
George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation, 136
Geyer MA. *See* Ralph-Williams RJ
Ghate M. *See* Arvindakshan M
Giordani B. *See* Starkman MN
Gitlin MJ. *See* Altshuler LL; Bartzokis G
Glahn DC, Therman S, Manninen M, Huttunen M, Kaprio J, Lönnqvist J, Cannon TD. Spatial working memory as an endophenotype in schizophrenia, 624
Glatt SJ. *See* Faraone SV
Goff DC. *See* Weiss AP
Gold JM. *See* Carpenter WT
Gorman JM. *See* Sullivan GM
Gorwood P, Limosin F, Batel P, Hamon M, Adès J, Boni C. The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure, 85
Grabner A. *See* Zimmermann U
Grados M. *See* Nestadt G
Grappi S, Nanni G, Leggio B, Rauggi R, Scheggi S, Masi F, Gambarana C. The efficacy of reboxetine in preventing and reverting a condition of escape deficit in rats, 890
Gray JA. *See* Lange K
Gray NA. *See* Manji HK
Grech A. *See* Schulze K
Green MF, Mintz J, Salveson D, Nuechterlein KH, Breitmeyer B, Light GA, Braff DL. Visual masking as a probe for abnormal gamma range activity in schizophrenia, 1114
Groll C. *See* Frodl T
Grote NK, Frank E. Difficult-to-treat depression: The role of contexts and comorbidities, 660
Grübel C. *See* Umbricht D
Grünhage F. *See* Jönsson EG
Grunhaus L, Schreiber S, Dolbert OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression, 324
Grunwald T, Boutros NN, Pezer N, von Oertzen J, Fernández G, Schaller C, Elger CE. Neuronal substrates of sensory gating within the human brain, 511
Gunning-Dixon F. *See* Szeszko PR
Gupta MA. *See* Lanius RA
Gur RE. *See* Turetsky BI
Gustavsson JP. *See* Jönsson EG
Gyulai L, Bauer M, Bauer MS, García-Espana F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge, 899

Hagino H. *See* Takahashi T
Hajós M. *See* Krause M
Hamblin MW. *See* Kohen R
Hamon M. *See* Gorwood P
Hariri AR, Mattay VS, Tessitore A, Fera F, Weinberger DR. Neocortical modulation of the amygdala response to fearful stimuli, 494
Haroutunian VH. *See* Hof PR
Harrington R, Myatt T. Is preadolescent mania the same condition as adult mania? A British perspective, 961
Heaton RK. *See* Evans JD
Heckers S. *See* Weiss AP
Hellander M. Pediatric bipolar disorder: The parent advocacy perspective, 935
Hen R. *See* Ralph-Williams RJ
Henn FA. *See* Sartorius A
Hennen J. *See* Henry ME
Henningsen H. *See* Knecht S
Henry ME, Kaufman MJ, Hennen J, Michelson D, Schmidt ME, Stoddard E, Vukovic AJ, Barreira PJ, Cohen BM, Renshaw PF. Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment, 100
Herman JP, Renda A, Bodie B. Norepinephrine–gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: Effects of reboxetine on GABAergic neurons, 166
Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder, 431
Hill D. *See* McCaddon A
Hirshfeld-Becker DR, Biederman J, Calltharp S, Rosenbaum ED, Faraone SV, Rosenbaum JF. Behavioral inhibition and disinhibition as hypothesized precursors to psychopathology: Implications for pediatric bipolar disorder, 985
Hoehn M. *See* Sartorius A
Hoehn-Saric R. *See* Nestadt G
Hof PR, Haroutunian VH, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia, 1075
Hoffmann WE. *See* Krause M
Holcomb HH. *See* Lahti AC
Hollis K. *See* Rohlff C

Holsboer F. *See* Zimmermann U
Honer WG. *See* Smith GN
Hoofnagle L. *See* Lewis L
Hopper J. *See* Lanius RA
Horrobin DF. *See* Arvindakshan M
Hozack N. *See* Paulus MP
Huber T. *See* Umbricht D
Hudson P. *See* McCaddon A
Hugdahl K, Rund BR, Lund A, Asbjørnsen A, Egeland J, Landrø NI, Roness A, Stordal KI, Sundet K. Attentional and executive dysfunctions in schizophrenia and depression: Evidence from dichotic listening performance, 609
Hume JH. *See* Kowatch RA
Hundt W. *See* Zimmermann U
Huttunen M. *See* Glahn DC

Ichimiya T. *See* Oda K
Imamura T. *See* Nakata K
Ishida R. *See* Oda K

Jäger M. *See* Frodl T
Jahn H. *See* Kiefer F
Janowsky DS. *See* Overstreet DH
Jasiukaitis PA. *See* Neylan TC
Jatlow PI. *See* George TP
Jeste DV. *See* Dolder CR; Evans JD
Joanette Y. *See* Lévesque J
Johnson SC. *See* Turetsky BI
Johnstone EC. *See* Warwick MM
Jones EG. *See* Molnar M
Jönsson EG, Cichon S, Gustavsson JP, Grünhage F, Forslund K, Mattila-Everden M, Rylander G, Åsberg M, Farde L, Propping P, Nöthen MM. Association between a promoter dopamine D2 receptor gene variant and the personality trait detachment, 577

Kagan J. *See* Schwartz CE
Kaprio J. *See* Glahn DC
Kasper S. *See* Stastny J
Kaufman MJ. *See* Henry ME
Kawaski Y. *See* Takahashi T
Keck PE Jr, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression, 671
Kelley M. *See* Thompson PM
Kelsey D. *See* Michelson D
Ketter T. *See* Chang K; Sachs GS
Kiefer F, Jahn H, Koester A, Montkowski A, Reinscheid RK, Wiedemann K. Involvement of NMDA receptors in alcohol-mediated behavior: Mice with reduced affinity of the NMDA R1 glycine binding site display an attenuated sensitivity to ethanol, 345
Klimek V. *See* Ordway GA
Klin A. *See* Tsatsanis KD
Knecht S, Ellger T, Breitenstein C, Ringelstein EB, Henningsen H. Changing cortical excitability with low-frequency transcranial magnetic stimulation can induce sustained disruption of tactile perception, 175
Koester A. *See* Kiefer F
Kohen R, Neumaier JF, Hamblin MW, Edwards E. Congenitally learned helpless rats show abnormalities in intracellular signaling, 520
Koller R. *See* Umbricht D
Konstantinidis A. *See* Stastny J
Kopala LC. *See* Smith GN
Kosten TR. *See* George TP
Kovalik E. *See* Quintana J
Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA. Combination pharmacotherapy in children and adolescents with bipolar disorder, 978
Krause M, Hoffmann WE, Hajós M. Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats, 244
Krishan KRR. *See* Taylor WD
Krishnan KRR. Comorbidity and depression treatment, 701
Kromelis M. *See* Kowatch RA
Krystal JH. *See* Morgan CA III
Kupfer DJ. *See* Fagiolini A; Sachs GS
Kupfer DJ, Charney DS. "Difficult-to-treat" depression, 633 (editorial)
Kupka RW. *See* Breunis MN
Kurachi M. *See* Takahashi T
Kuroda S. *See* Nakata K
Kusumakar V. *See* MacMaster FP

Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA. Functional effects of antipsychotic drugs: Comparing clozapine with haloperidol, 601
Lai T-J. *See* Taylor WD
Lail KE. *See* Wozniak J
Landau S. *See* Chana G
Landrø NI. *See* Hugdahl K
Lang DJ. *See* Smith GN
Lange K. *See* Mataix-Cols D
Lange K, Williams LM, Young AW, Bullmore ET, Brammer MJ, Williams SCR, Gray JA, Phillips ML. Task instructions modulate neural responses to fearful facial expressions, 226
Lanius RA, Williamson PC, Hopper J, Densmore M, Boksman K, Gupta MA, Neufeld RWJ, Gati JS, Menon RS. Recall of emotion states in posttraumatic stress disorder: An fMRI investigation, 204
Lapointe JS. *See* Smith GN
Lavori P. *See* Sachs GS
Lawrie SM. *See* Warwick MM
Lebowitz B. *See* Sachs GS
LeDoux JE. *See* Sullivan GM
Lee S-H. *See* Taylor WD
Leggio B. *See* Grappi S
Leibenluft E, Charney DS, Pine DS. Researching the pathophysiology of pediatric bipolar disorder, 1009
Leinsinger G. *See* Frodl T
Lenoci M. *See* Neylan TC
Leroux J-M. *See* Lévesque J
Leverich GS. *See* Breunis MN
Lévesque J, Eugène F, Joanette Y, Paquette V, Mensour B, Beaudoin G, Leroux J-M, Bourgouin P, Beauregard M. Neural circuity underlying voluntary suppression of sadness, 502
Lewis DA. *See* Volk DW
Lewis L, Hoofnagle L. Treatment-resistant depression: The patient perspective, 635
Liang K-Y. *See* Nestadt G
Liberzon I. *See* Phan KL
Light GA. *See* Green MF
Limosin F. *See* Gorwood P
Linden M. *See* Senkowski D
Lloyd A. *See* McCaddon A
Lönnqvist J. *See* Glahn DC
Lu PH. *See* Bartzokis G
Luckenbaugh DA. *See* Frye MA
Lund A. *See* Hugdahl K

Mackinaw-Koons B. *See* Fristad MA
MacMaster FP, Carrey N, Sparkes S, Kusumakar V. Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder, 184
Mahadik SP. *See* Arvindakshan M
Maj M. *See* Galderisi S
Makino KK. *See* Hibbeln JR
Mallinckrodt CH, Sanger TM, Dubé S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson

GD. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data, 754
Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, Zarate CA Jr, Charney DS. Enhancing neuronal plasticity and cellular resistance to develop novel, improved therapeutics for difficult-to-treat depression, 707
Manninen M. *See* Glahn DC
Marangell L. *See* Sachs GS
March JS. Acute stress disorder in youth: A multivariate prediction model, 809
Marcina J. *See* Clark CR
Marder SR. *See* Quintana J
Marenco S, Weinberger DR, Schreurs BG. Single-cue delay and trace classical conditioning in schizophrenia, 390
Marmar CR. *See* Neylan TC
Martin CE. *See* Hibbeln JR
Masi F. *See* Grappi S
Mataix-Cols D, Cullen S, Lange K, Zelaya F, Andrew C, Amaro E, Brammer MJ, Williams SCR, Speckens A, Phillips ML. Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers, 482
Matar M. *See* Cohen H
Mathé AA. *See* Overstreet DH
Matsuda T. *See* Oda K
Mattay VS. *See* Bertolino A; Hariri AR
Mattila-Everden M. *See* Jönsson EG
Matsushima E. *See* Oda K
May W. *See* Ordway GA
Mazziotta JC. *See* Quintana J
Mbakop MP. *See* Celano E
McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland B. Alzheimer's disease and total plasma aminothiols, 254
McDonald C. *See* Schulze K
McElroy SL. *See* Keck PE Jr
McFarlane AC. *See* Clark CR
McGlashan T. *See* Bremner JD
McInnis MG. *See* Schulze TG
McLeod MN. *See* Davidson JRT
McMahon FJ. *See* Schulze TG
McMullin KG. *See* Schwartz CE
McNally RJ. Psychological mechanisms in acute response to trauma, 779
McQuoid DR. *See* Taylor WD
Medoff DR. *See* Lahti AC
Meisenzahl EM. *See* Frodl T
Meltzer HY, Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia, 265–corr
Menon RS. *See* Lanius RA
Menon V. *See* Tamm L
Mensour B. *See* Lévesque J
Metzler TJ. *See* Neylan TC
Michelson D. *See* Henry ME
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies, 112
Mick E. *See* Biederman J; Braaten EB
Mick E, Biederman J, Pandina G, Faraone SV. A preliminary meta-analysis of the child behavior checklist in pediatric bipolar disorder, 1036
Miklowitz D. *See* Sachs GS
Milton D. *See* Michelson D
Minov C. *See* Bondy B
Mintz J. *See* Bartzokis G; Green MF
Moberg PJ. *See* Turetsky BI
Molenberghs G. *See* Mallinckrodt CH
Möller H-J. *See* Bondy B; Frodl T
Molnar M, Potkin SG, Bunney WE Jr, Jones EG. mRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients, 39
Monteleone P. *See* Galderisi S
Montkowski A. *See* Kiefer F
Monuteaux MC. *See* Biederman J; Braaten EB; Wozniak J
Moraschi S. *See* Begni S
Morgan CA III, Krystal JH, Southwick SM. Toward early pharmacological posttraumatic stress intervention, 834
Morris P. *See* Clark CR
Mucci A. *See* Galderisi S
Murata Y. *See* Oda K
Murphy AD. *See* Norris FH
Murray RM. *See* Schulze K
Myatt T. *See* Harrington R

Nakamura K. *See* Takahashi T
Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y, Kuroda S. The human dihydropyrimidinase-related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia, 571
Nanni G. *See* Grappi S
Neale MC. *See* Silberg JL
Nelson EB. *See* Keck PE Jr
Nestadt G, Addington A, Samuels J, Liang K-Y, Bienvenu OJ, Riddle M, Grados M, Hoehn-Saric R, Cullen B. The identification of OCD-related subgroups based on comorbidity, 914
Nestler EJ. Comment on "Preclinical models: Status of basic research in depression," 279–corr (reply)
Neufeld RWJ. *See* Lanius RA
Neumaier JF. *See* Kohen R
Neumann-Haefelin C. *See* Sartorius A
Neumeister A. *See* Stastny J
Neylan TC, Jasiukaitis PA, Lenoci M, Scott JC, Metzler TJ, Weiss DS, Schoenfeld FB, Marmar CR. Temporal instability of auditory and visual event-related potentials in posttraumatic stress disorder, 216
Nichols TE. *See* Phan KL
Nierenberg AA. *See* Sachs GS
Nishikawa T. *See* Oda K
Nohara S. *See* Takahashi T
Nolen WA. *See* Breunis MN
Noll DC. *See* Perlstein WM; Phan KL
Norris FH, Murphy AD, Baker CK, Perilla JL. Severity, timing, and duration of reactions to trauma in the population: An example from Mexico, 769
Nöthen MM. *See* Jönsson EG
Nudmamud S, Reynolds LM, Reynolds GP. N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: A postmortem study, 1139
Nuechterlein KH. *See* Bartzokis G; Green MF

Oda K, Okubo Y, Ishida R, Murata Y, Ohta K, Matsuda T, Matsushima E, Ichimiya T, Suhara T, Shibuya H, Nishikawa T. Regional cerebral blood flow in depressed patients with white matter magnetic resonance hyperintensity, 150
Ohta K. *See* Oda K
Okubo Y. *See* Oda K
O'Malley SS. *See* George TP

Ordway GA, Schenk J, Stockmeier CA, May W, Klimek V. Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression, 315
Ortiz-Portillo E. *See* Quintana J
Otto MW. *See* Sachs GS
Overstreet DH, Daws LC, Yadid G, Friedman E, Mathé AA, Janowsky DS. Comment on "Preclinical models: Status of basic research in depression," 268–corr
Owzar K. *See* Turetsky BI

Palmer BW. *See* Evans JD
Pandina G. *See* Mick E
Paquette V. *See* Lévesque J
Parr T. *See* Silberg JL
Patterson T. *See* Evans JD
Paulsen JS. *See* Evans JD
Paulus MP. *See* Ralph-Williams RJ
Paulus MP, Braff DL. Chaos and schizophrenia: Does the method fit the madness?, 3
Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA. Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation, 65
Payne JL. *See* Manji HK
Payne ME. *See* Taylor WD
Pazzaglia PJ. *See* Frye MA
Perez J. *See* Begni S
Perilla JL. *See* Norris FH
Perl DP. *See* Hof PR
Perlstein WM, Dixit NK, Carter CS, Noll DC, Cohen JD. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia, 25
Pezer N. *See* Grunwald T
Phan KL, Taylor SF, Welsh RC, Decker LR, Noll DC, Nichols TE, Britton C, Liberzon I. Activation of the medial prefrontal cortex and extended amygdala by individual ratings of emotional arousal: A fMRI study, 211
Phillips ML. *See* Lange K; Mataix-Cols D
Piegari G. *See* Galderisi S
Pine DS. *See* Leibenluft E
Pine DS. Developmental psychobiology and response to threats: Relevance to trauma in children and adolescents, 796
Polak D. *See* Grunhaus L
Polanczyk G. *See* Tramontina S
Popoli M. *See* Celano E
Post R. *See* Bertolino A
Post RM. *See* Breunis MN; Frye MA
Potkin SG. *See* Molnar M
Potter WZ. *See* Mallinckrodt CH
Propping P. *See* Jönsson EG

Quintana J, Wong T, Ortiz-Portillo E, Kovalik E, Davidson T, Marder SR, Mazziotta JC. Prefrontal – posterior parietal networks in schizophrenia: Primary dysfunctions and secondary compensations, 12
Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia, 1099
Quiroz JA. *See* Manji HK

Racagni G. *See* Celano E
Rakow R. *See* Bertolino A
Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system, 352
Ranjekar PK. *See* Arvindakshan M
Rapaport MH. *See* Wang X-F
Rauch SL. *See* Schwartz CE; Weiss AP
Rauggi R. *See* Grappi S
Read LL. *See* Richardson MA
Regland B. *See* McCaddon A
Reilly MA. *See* Richardson MA
Reimherr FW. *See* Michelson D
Reinscheid RK. *See* Kiefer F
Reiss AL. *See* Chang K; Tamm L
Renda A. *See* Herman JP
Renshaw PF. *See* Henry ME
Reynolds GP. *See* Nudmamud S
Reynolds LM. *See* Nudmamud S
Richards J. *See* Wozniak J
Richardson MA, Read LL, Clelland JD, Chao HM, Reilly MA, Romstad A, Suckow RF. Phenylalanine hydroxylase gene in psychiatric patients: Screening and functional assay of mutations, 543
Riddle M. *See* Nestadt G
Rillosi L. *See* Begni S
Ringelstein EB. *See* Knecht S
Rogers J. *See* Williamson DE
Rogers S. *See* Bartzokis G
Rohde LA. *See* Tramontina S
Rohlff C, Hollis K. Modern proteomic strategies in the study of complex neuropsychiatric disorders, 847
Romstad A. *See* Richardson MA
Roness A. *See* Hugdahl K
Rosenbaum ED. *See* Hirshfeld-Becker DR
Rosenbaum JF. *See* Hirshfeld-Becker DR; Sachs GS
Rosenthal NE. *See* Stastny J
Rothschild AJ. Challenges in the treatment of depression with psychotic features, 680
Rourke BP. *See* Tsatsanis KD
Rubinow DR. *See* Frye MA
Rudorfer M. *See* Sachs GS
Rund BR. *See* Hugdahl K
Rupprecht R. *See* Bondy B
Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression, 743
Rutter M. *See* Silberg JL
Ryan ND. *See* Williamson DE
Rylander G. *See* Jönsson EG

Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF. Rationale, design, and methods of Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 1021
Sakai A. *See* Nakata K
Salchner P. *See* Singewald N
Salveson D. *See* Green MF
Samuels J. *See* Nestadt G
Sanger TM. *See* Mallinckrodt CH
Sartorius A, Neumann-Haefelin C, Vollmayr B, Hoehn M, Henn FA. Choline rise in the rat hippocampus induced by electroconvulsive shock treatment, 620
Schacter DL. *See* Weiss AP
Schaller C. *See* Grunwald T
Scheggi S. *See* Grappi S
Schenk J. *See* Ordway GA
Schmid L. *See* Umbricht D
Schmidt ME. *See* Henry ME
Schmitz M. *See* Tramontina S
Schoenfeld FB. *See* Neylan TC
Schreiber S. *See* Grunhaus L
Schreurs BG. *See* Marenco S
Schteingart DE. *See* Starkman MN
Schuckit MA. *See* Paulus MP
Schüle C. *See* Bondy B

Schultz RT. *See* Tsatsanis KD
Schulze K, McDonald C, Frangou S, Sham P, Grech A, Toulopoulou T, Walshe M, Sharma T, Sigmundsson T, Taylor M, Murray RM. Hippocampal volume in familial and nonfamilial schizophrenic probands and their unaffected relatives, 562
Schulze TG, Chen Y-S, Badner JA, McInnis MG, DePaulo JR Jr, McMahon FJ. Additional, physically ordered markers increase linkage signal for bipolar disorder on chromosome 18q22, 239
Schwartz CE, Wright CI, Shin LM, Kagan J, Whalen PJ, McMullin KG, Rauch SL. Differential amygdalar response to novel versus newly familiar neutral faces: A functional MRI probe developed for studying inhibited temperament, 854
Schwarz MJ. *See* Bondy B; Stastny J
Scott JC. *See* Neylan TC
Senkowski D, Linden M, Zubrägel D, Bär T, Galliant J. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder, 304
Sethuraman G. *See* Kowatch RA
Seto H. *See* Takahashi T
Sham P. *See* Schulze K
Sharma T. *See* Schulze K
Sharp T. *See* Singewald N
Shaw M. *See* Clark CR
Sheline YI. *See* Barch DM
Shelton-Repella J. *See* Bertolino A
Shibuya H. *See* Oda K
Shin LM. *See* Schwartz CE
Sigmundsson T. *See* Schulze K
Silberg JL, Parr T, Neale MC, Rutter M, Angold A, Eaves LJ. Maternal smoking during pregnancy and risk to boys' conduct disturbance: An examination of the causal hypothesis, 130
Singewald N, Salchner P, Sharp T. Induction of c-fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs, 275
Singh RP, Smith DJ. Genome scale mapping of brain gene expression, 1069
Sitasawad S. *See* Arvindakshan M
Skrabo A. *See* Umbricht D
Smith DJ. *See* Singh RP
Smith GN, Lang DJ, Kopala LC, Lapointe JS, Falkai P, Honer WG. Developmental abnormalities of the hippocampus in first-episode schizophrenia, 555
Snyder AZ. *See* Barch DM
Sonkkilla C. *See* Clark CR
Sorrentino D. *See* Galderisi S
Soufer R. *See* Bremner JD
Southwick SM. *See* Bremner JD; Morgan CA III
Sparkes S. *See* MacMaster FP
Speckens A. *See* Mataix-Cols D
Spencer T. *See* Michelson D
Sporn J. *See* Manji HK
Spring K. *See* Zimmermann U
Staib LH. *See* Bremner JD
Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in learning associated with increase in hippocampal formation volume, 233
Stassen H. *See* Umbricht D
Stastny J, Konstantinidis A, Schwarz MJ, Rosenthal NE, Vitouch O, Kasper S, Neumeister A. Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy, 332
Steffens DC. *See* Taylor WD
Steiner H. *See* Chang K
Stockmeier CA. *See* Ordway GA
Stoddard E. *See* Henry ME
Stordal KI. *See* Hugdahl K
Suckow RF. *See* Richardson MA
Suhara T. *See* Oda K
Sullivan GM, Apergis J, Gorman JM, LeDoux JE. Rodent doxapram model of panic: Behavioral effects and c-fos immunoreactivity in the amygdala, 863
Sumiyoshi T. *See* Meltzer HY
Sun X. *See* Chen B
Sundet K. *See* Hugdahl K
Suppes T. *See* Breunis MN
Suzuki M. *See* Takahashi T
Szeszko PR, Gunning-Dixon F, Ashtari M, Snyder PJ, Lieberman JA, Bilder RM. Reversed cerebellar asymmetry in men with first-episode schizophrenia, 450

Takahashi T, Suzuki M, Kawasaki Y, Hagino H, Yamashita I, Nohara S, Nakamura K, Seto H, Kurachi M. Perigenual cingulate gyrus volume in patients with schizophrenia: A magnetic resonance imaging study, 593
Takaki M. *See* Nakata K
Tamm L, Menon V, Reiss AL. Abnormal prefrontal cortex function during response inhibition in Turner syndrome: Functional magnetic resonance imaging evidence, 107
Tamminga CA. *See* Lahti AC
Tanaka Y. *See* Nakata K
Tannenbaum B, Anisman H. Impact of chronic intermittent challenges in stressor-susceptible and resilient strains of mice, 292
Taylor M. *See* Schulze K
Taylor SF. *See* Phan KL
Taylor WD, Steffens DC, McQuoid DR, Payne ME, Lee S-H, Lai T-J, Krishan KRR. Smaller orbital frontal cortex volumes associated with functional disability in depressed elders, 144
Termine A. *See* George TP
Tessitore A. *See* Hariri AR
Thase ME. *See* Rush AJ; Sachs GS
Therman S. *See* Glahn DC
Thomas KM. *See* Durston S
Thompson PM, Kelley M, Yao J, Tsai G, van Kammen DP. Elevated cerebrospinal fluid SNAP-25 in schizophrenia, 1133
Tiraboschi E. *See* Celano E
Tochon-Danguy HJ. *See* Clark CR
Tollefson GD. *See* Mallinckrodt CH
Tottenham NT. *See* Durston S
Toulopoulou T. *See* Schulze K
Tramontina S, Schmitz M, Polanczyk G, Rohde LA. Juvenile bipolar disorder in Brazil: Clinical and treatment findings, 1043
Tsai G. *See* Thompson PM
Tsatsanis KD, Rourke BP, Klin A, Volkmar FR, Cicchetti D, Schultz RT. Reduced thalamic volume in high-functioning individuals with autism, 121
Tsuang MT. *See* Faraone SV
Turetsky BI, Moberg PJ, Owzar K, Johnson SC, Doty RL, Gur RE. Physiologic impairment of olfactory stimulus processing in schizophrenia, 403

Ujike H. *See* Nakata K

Ulug AM. *See* Durston S
Umbricht D, Koller R, Schmid L, Skrabo A, Grübel C, Huber T, Stassen H. How specific are deficits in mismatch negativity generation to schizophrenia, 1121

van Kammen DP. *See* Thompson PM
van Meter S. *See* Davidson JRT
Vanderham E. *See* Frye MA
Vermetten E. *See* Bremner JD
Vessicchio JC. *See* George TP
Vitouch O. *See* Stastny J
Volk DW, Lewis DA. Effects of a mediodorsal thalamic lesion on prefrontal inhibitory circuitry: Implications for schizophrenia, 385
Volkmar FR. *See* Tsatsanis KD
Vollmayr B. *See* Sartorius A
von Oertzen J. *See* Grunwald T
Vukovic AJ. *See* Henry ME
Vythilingam M. *See* Bremner JD

Walshe M. *See* Schulze K
Wang D. *See* Wang X-F
Wang J-F. *See* Chen B
Wang X-F, Wang D, Zhu W, Delrahim KK, Dolnak D, Rapaport MH. Studies characterizing 60 kDa autoantibodies in subjects with schizophrenia, 361
Ward NM. *See* Blier P
Warwick MM, Lawrie SM, Beveridge A, Johnstone EC. Abnormal cerebral asymmetry and schizophrenia in a subject with Klinefelter's syndrome (XXY), 627
Weber DL. *See* Clark CR
Weiler MA. *See* Lahti AC
Weinberg WA. *See* Kowatch RA
Weinberger DR. *See* Bertolino A; Hariri AR; Marenco S
Weisler RH. *See* Davidson JRT
Weiss AP, Schacter DL, Goff DC, Rauch SL, Alpert NM, Fischman AJ, Heckers S. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia, 48
Weiss DS. *See* Neylan TC
Welsh RC. *See* Phan KL
Wernicke J. *See* Michelson D
West SA. *See* Michelson D
Whalen PJ. *See* Schwartz CE
Whybrow PC. *See* Gyulai L
Wiedemann K. *See* Kiefer F
Williams LM. *See* Lange K
Williams SCR. *See* Lange K; Mataix-Cols D
Williamson DE, Coleman K, Bacanu S-A, Devlin BJ, Rogers J, Ryan ND, Cameron JL. Heritability of fearful-anxious endophenotypes in infant rhesus macaques: A preliminary report, 284
Williamson PC. *See* Lanius RA
Wisniewski SR. *See* Sachs GS
Wong T. *See* Quintana J
Wozniak J. *See* Biederman J
Wozniak J, Monuteaux M, Richards J, Lail KE, Faraone SV, Biederman J. Convergence between structured diagnostic interviews and clinical assessment on the diagnosis of pediatric-onset mania, 938
Wright CI. *See* Schwartz CE

Yadid G. *See* Overstreet DH
Yamashita I. *See* Takahashi T
Yang Y. *See* Durston S
Yao J. *See* Thompson PM
Young AW. *See* Lange K
Young LT. *See* Chen B
Youngstrom EA. *See* Carlson GA

Zarate CA Jr. *See* Manji HK
Zelaya F. *See* Mataix-Cols D
Zetzsche T. *See* Frodl T
Zhu W. *See* Wang X-F
Zhuang X. *See* Ralph-Williams RJ
Zimmermann U, Hundt W, Spring K, Grabner A, Holsboer F. Hypothalamic-pituitary-adrenal system adaptation to detoxification in alcohol-dependent patients is affected by family history of alcoholism, 75
Zohar J. *See* Cohen H
Zubrägel D. *See* Senkowski D
Zwanzger P. *See* Bondy B

Subject Index to Volume 53

Acute stress disorder. *See also* Posttraumatic stress disorder
  in adolescents, 809
  in children, 809
  psychological mechanisms, 779
Adolescents. *See also* Children
  acute stress disorder in, 809
  bipolar disorder in, 978
  posttraumatic stress disorder in
    description of, 765, 809
    treatment of, 827
α_2-Adrenoceptors
  agonist binding to, in locus coeruleus, 315
Aging. *See also* Elderly
  schizophrenia and, 422
Alcohol withdrawal
  dopamine transporter gene in, 85
  hypothalamic-pituitary-adrenal system effects, 75
Alcoholism
  familial history of, 75
  hypothalamic-pituitary-adrenal system and, 75
  NMDA-receptor complex and, 345
Alzheimer's disease
  aminothiols and, 254
  cysteine levels in, 254
  glutathione levels in, 254
  homocysteine levels in, 254
Aminothiols
  Alzheimer's disease and, 254
Amygdala
  activation of, by individual ratings of emotional arousal, 211
  c-fos immunoreactivity in, 854
  fear-related responses, 226, 494
  neural responses to fearful facial expressions and, 226
  novel versus familiar stimuli responses, 854
  volume of, depression and, 338
Animal models
  choline rise in rat hippocampus induced by electroconvulsive shock treatment, 620
  doxapram model of panic, 863
  learned helplessness, 520
  posttraumatic stress disorder, 463
  reboxetine, 890
  valproate effects on hyperactivity, 352
Anterior cingulate
  in bipolar disorder, 1086
  cytoarchitecture of, 1086
  emotional states in posttraumatic stress disorder and, 204
  in major depression, 1086
  in schizophrenia, 1086
  volume reduction of, in schizophrenia, 592
Antipsychotic drugs
  atypical, tardive dyskinesia with, 1143
  clozapine, 601
  functional effects of, 601
  haloperidol, 601
Anxiety
  animal models of, 863
  attention-deficit/hyperactivity disorder and, 93
  drugs that induce symptoms of, 275
  genetic studies of, 284
  heritability of, 284
  neural correlates of, 482
  obsessive-compulsive disorder-related, 482
Anxiogenic drugs
  c-fos expression induced by, 275
Atomoxetine
  attention-deficit/hyperactivity disorder treated using, 112
Attention
  dysfunctions of, in schizophrenia, 608
Attention-deficit/hyperactivity disorder
  anxiety disorders and, 93
  atomoxetine for, 112
  bipolar disorder and, 952
  prefrontal cortex in
    proton magnetic resonance spectroscopy evaluations of, 184
  striatal activation patterns in children with, 871
Atypical antipsychotic drugs
  cognition in schizophrenia improved using, 265–corr
  tardive dyskinesia secondary to, 1143
Auditory event-related potentials
  in posttraumatic stress disorder, 216
Auditory sensory gating, in hippocampus
  schizophrenia models of, 244
  studies of, 510
Autism
  thalamus' role in, 121
Autoantibodies
  in schizophrenia, 361

Behavioral inhibition and disinhibition
  pediatric bipolar disorder and, 985
Bipolar disorder
  adolescents, 978
  anterior cingulate cortex in, 1086
  calcium/calmodulin dependent protein kinase II in, 39
  chromosome 18q22 and, 239
  familial, 1059
  N-acetylaspartate levels
    deficit, 1133
    description of, 906
    familial bipolar disorder, 1059

© 2003 Society of Biological Psychiatry

0006-3223/03/$30.00
doi:10.1016/S0006-3223(03)00504-3

N-acetylaspartylglutamate deficits in, 1133
neuronal pathology in hippocampal area of patients with, 906
pediatric
adult bipolar disorder vs., 952
attention-deficit/hyperactivity disorder and, 952
behavior checklist for, 1036
behavioral inhibition and disinhibition as precursors to, 985
case studies of, 1043
clinical assessment of, 938
conduct disorder and, 952
description of, 931 (editorial)
diagnosis of, 938
evolution of, 945
family psychoeducation for, 1000
genetics of, 970
lithium for, 978
N-acetylaspartate levels in, 1059
parent advocacy perspective of, 935
parents with bipolar disorder, 945
pathophysiology of, 1009
pervasive manic symptoms in, 1050
pharmacotherapy for, 978
precursors to, 985
psychoeducation for, 1000
structured interviews for, 938
studies of, 1043, 1050
Systematic Treatment Enhancement Program for Bipolar Disorder, 1021
rapid-cycling, thyroid hypofunction in patients with, 899
serum interleukin-2 receptor in, 157
superior temporal gyrus deficits of N-acetylaspartate and N-acetylaspartylglutamate in, 1133
T cells in, 157
T-brain–1 in, 39
treatment of
acceleration and augmentation strategies for, 691
pharmacologic, 671
Brain
development of, schizophrenia-related dysregulations in, 412
gene expression, genome scale mapping of, 1069
sensory gating
in hippocampus, 244
neuronal substrates of, 511

Calcium/calmodulin dependent protein kinase II
in bipolar disorder, 39
psychotropic drug regulation of, 442
Cannabis-sensitive dopaminergic markers
schizophrenia and, 583
Catecholamines
seasonal affective disorder and, 332
Cerebellar asymmetry
schizophrenia and
first-episode, 450
in Klinefelter's syndrome patient, 627
Cerebral blood flow, regional
clozapine effects, 601
in depression, 150
haloperidol effects, 601
Cerebrospinal fluid
SNAP-25 levels, in schizophrenia, 1133
somatostatin levels, in depression, 180
Cerebrum
blood volume, selective serotonin reuptake inhibitor discontinuation effects on, 100
function of, in posttraumatic stress disorder during verbal working memory updating, 474
regional blood flow. *See also* Cerebral blood flow
c-fos
expression, anxiogenic drug induction of, 275
immunoreactivity in, 863
Chaos
schizophrenia and, 3
Childhood sexual abuse
posttraumatic stress disorder secondary to, 879
Children. *See also* Adolescents
acute stress disorder in, 809
bipolar disorder in
adult bipolar disorder vs., 952
attention-deficit/hyperactivity disorder and, 952
behavior checklist for, 1036
behavioral inhibition and disinhibition as precursors to, 985
case studies of, 1043
clinical assessment of, 938
conduct disorder and, 952
description of, 931 (editorial)
diagnosis of, 938
evolution of, 945
family psychoeducation for, 1000
genetics of, 970
lithium for, 978
N-acetylaspartate levels in, 1059
parent advocacy perspective of, 935
parents with bipolar disorder, 945
pathophysiology of, 1009
pervasive manic symptoms in, 1050
pharmacotherapy for, 978
precursors to, 985
psychoeducation for, 1000
structured interviews for, 938
studies of, 1043, 1050
Systematic Treatment Enhancement Program for Bipolar Disorder, 1021
developmental psychobiology, 796
inhibited temperament in, 854
posttraumatic stress disorder in
description of, 765, 809
treatment of, 827
striatal activation patterns in, 871
threat response in, 796
trauma in
early interventions for, 765 (editorial)

treatment of, 827
Chromium picolinate
atypical depression treated using, 261
Chromosome 8p21
dihydropyrimidinase-related protein 2 gene on, in paranoid-type schizophrenia, 571
Chromosome 18q22
bipolar disorder and, 239
Cingulate gyrus
anterior
in bipolar disorder, 1086
cytoarchitecture of, 1086
emotional states in posttraumatic stress disorder and, 204
in major depression, 1086
in schizophrenia, 1086
volume reduction of, in schizophrenia, 592
perigenual, in schizophrenia
Classical conditioning
schizophrenia and, 390
Clozapine, 601
Cognition
in schizophrenia, atypical antipsychotic drugs effect on, 265–corr
Cognitive behavioral therapy
posttraumatic stress disorder treated with, 817
Cognitive control, 871
Comorbidity
with depression, 660, 701
obsessive-compulsive disorder subgroups based on, 914
Conduct disorder
bipolar disorder and, 952
maternal smoking during pregnancy and, 130
Cortical excitability
transcranial magnetic stimulation, 175
Cortical signaling
in generalized anxiety disorder, 304
Cushing's syndrome
hippocampal formation volume and, 233
Cysteine
in Alzheimer's disease, 254

Decision making
in methamphetamine-dependent subjects, 65
Declarative memory for emotionally valenced words
neural correlates for, in women with posttraumatic stress disorder, 879
Delirium tremens
dopamine transporter gene in, 85
Depression. *See also* Major depression
agonist binding to α_2-adrenoceptors in locus coeruleus in, 315
amygdala volume and, 338
atypical
characteristics of, 261
chromium picolinate for, 261
bipolar, treatment of
acceleration and augmentation strategies for, 691
pharmacologic, 671
cerebrospinal fluid somatostatin levels in, 180
comorbidities, 660, 701
difficult-to-treat. *See also* Depression, treatment-resistant
advances in, 633 (editorial)
comorbidities with, 660
contexts for, 660
neuronal plasticity enhancements and cellular resistance for developing therapeutics for, 707
patient's perspective on, 635
psychosocial contexts for, 660
research issues in the study of, 743
treatment effects in longitudinal clinical trials assessed and interpreted, 754
elderly
orbital frontal cortex volumes associated with functional disability, 144
electroconvulsive therapy for, 324
first-episode, amygdala volume in, 338
functional impairments associated with, 144
genetic studies of, 284
hippocampal changes in, 530
5-HT_{1A} agonists for, 193
orbital frontal cortex and, in depressed elders, 144
preclinical models of, 268–corr
prefrontal cortex
white matter neurons in, 39
with psychotic features, 680
regional cerebral blood flow in, 150
repetitive transcranial magnetic stimulation of, 324
serotonin for, 193
treatment of
assessment and interpretation of effects of, 754
comorbidity and, 701
treatment-resistant. *See also* Depression, difficult-to-treat
classification of, 640
definition of, 649
diagnosis of, 649
patient's perspective on, 635
subtype issues, 640
working memory deficits, 376
Desipramine
GAP-43 expression regulated by, 530
Developmental psychobiology
trauma reactions and, 796
Dichotic listening performance
attention and executive dysfunctions in schizophrenia determined using, 609
Diet
essential polyunsaturated fatty acids and, 431
Difficult-to-treat depression
advances in, 633 (editorial)
comorbidities with, 660
contexts for, 660
neuronal plasticity enhancements and cellular resistance for developing therapeutics for, 707
patient's perspective on, 635
psychosocial contexts for, 660
research issues in the study of, 743

treatment effects in longitudinal clinical trials assessed and interpreted, 754
Dihydropyrimidinase-related protein 2, 571
Dopamine D_2 receptor gene
personality traits and, 577
Dopamine transporter
tetrahydrocannabinol effects on, in schizophrenia, 585
valproate effects, 352
Dopamine transporter gene
alcohol-withdrawal seizures and, 85
delirium tremens and, 85
Doxapram
panic attacks and, 863

Eating disorders
neuroactive steroids effect, 921
neurocognitive functioning in patients with, 921
Elderly
depression in
orbital frontal cortex volumes associated with functional disability, 144
Electroconvulsive shock treatment
choline rise in hippocampus induced by, 620
Emotional arousal
medial prefrontal cortex activation in, 211
Emotional states
in posttraumatic stress disorder, 204
suppression of, neural circuitry associated with, 502
Endophenotype
working memory used as, in schizophrenia, 624
Essential polyunsaturated fatty acid
dietary influences on, 431
gender effects on, 431
in schizophrenia, 56
smoking effects on, 431
Ethanol
glutamate antagonism by, 345
Event-related potentials
in posttraumatic stress disorder, 216
Executive dysfunction
in schizophrenia, 608
in Turner syndrome, 107

Facial expressions, fearful
neural responses to, task instructions effect on, 226
Facial information processing
right lateral fusiform gyrus dysfunction during, in schizophrenia, 1099
Fear
amygdala responses to, neocortical modulation of, 494
c-fos expression and, 275
heritability of behaviors associated with, 284
neural responses to, task instructions effect on, 226
Functional magnetic resonance imaging
amygdala response to novel versus familiar stimuli, 854
anxiety associated with obsessive-compulsive disorder studied using, 482
emotional states in posttraumatic stress disorder analyzed using, 204
medial prefrontal cortex and extended amygdala activation by emotional arousal, 211

Gamma range activity
in schizophrenia, visual masking as a probe for, 1114
GAP-43 expression
desipramine regulation of, 530
G1001C polymorphism of *GRIN1* gene, 617
Gender
essential polyunsaturated fatty acids and, 431
Gene expression
brain, genome scale mapping of, 1069
Generalized anxiety disorder
cortical signal processing in, 304
serotonergic neurotransmission alterations in, 304
Genome scale mapping of brain gene expression, 1069
Glutamate
ethanol antagonism of, 345
Glutamic acid decarboxylase, 39
Glutathione
in Alzheimer's disease, 254
Gray matter
schizophrenia-related dysregulations in, 412
GRIN1 gene
G1001C polymorphism of, 617
schizophrenia and, 617

Haloperidol, 601
Hippocampus
auditory sensory gating in
in schizophrenia models, 244
studies of, 510
bipolar disorder, neuronal pathology in, 906
choline rise in, induced by electroconvulsive shock treatment, 620
Cushing's syndrome and, 233
depression-related changes, 530
developmental abnormalities of, in schizophrenia, 555
learning improvements effect on volume of, 233
in memory performance in schizophrenia, 48
neural responses to fearful facial expressions and, 226
in schizophrenia
developmental abnormalities, 555
recruitment of, 48
volume of, 562
Homocysteine
in Alzheimer's disease, 254
5-HT_{1A} agonists
depression treated with, 193
Hyperactivity
valproate effects on, in dopamine transporter knockdown mice, 352
Hypothalamic-pituitary-adrenal system
alcohol withdrawal effects on, 75
rapid-cycling bipolar disorder effects, 899

Inhibited temperament, 854
Interleukin-2 receptor

in bipolar disorder, 157
Intracellular signaling abnormalities
learned helplessness and, 520

Klinefelter's syndrome
cerebellar asymmetry and schizophrenia in patient with, 627

Latent class analysis, of obsessive-compulsive disorder, 914
Lateral fusiform gyrus dysfunction
during facial information processing, in schizophrenia, 1099
Learned helplessness
animal models of, 520
congenital, 520
Learning
hippocampal formation volume associated with improvement in, 233
Limbic regions
norepinephrine–gamma-aminobutyric acid interactions in, 166
Lipid peroxides
in schizophrenia, 56
Locus coeruleus
agonist binding to α_2-adrenoceptors in, 315

Magnetic resonance imaging
functional
amygdala response to novel versus familiar stimuli, 854
anxiety associated with obsessive-compulsive disorder studied using, 482
emotional states in posttraumatic stress disorder analyzed using, 204
medial prefrontal cortex and extended amygdala activation by emotional arousal, 211
white matter hyperintensity, in depression, 150
Magnetic resonance spectroscopy
hippocampal pathology in bipolar disorder patients assessed using, 906
proton, attention-deficit/hyperactivity disorder evaluations, 184
Major depression. *See also* Depression
anterior cingulate cortex in, 1086
with psychotic features, 680
substance P serum levels in, 538
Mania
pediatric-onset
adult mania vs., 961
diagnosis of, 938
pervasive symptoms of, 1050
Maternal smoking during pregnancy
conduct disturbance and, 130
Medial prefrontal cortex
activation of, by individual ratings of emotional arousal, 211
Men
cerebellar asymmetry in men with schizophrenia, 450
Methamphetamine
decision making in patients dependent on, 65
Mirtazapine
posttraumatic stress disorder treated using, 188
Mismatch negativity deficits
in schizophrenia, 1121

N-acetylaspartate
bipolar disorder and, 906, 1059, 1139
deficits of, in schizophrenia and bipolar disorder, 1139
N-acetylaspartylglutamate
bipolar disorder and, 1133
schizophrenia and, 1133
Neuroactive steroids
neurocognitive functioning in patients with eating disorders affected by, 921
Neuronal plasticity
desipramine effects on, 530
enhancing of, for developing improved therapeutics for depression, 707
Nimodipine
cerebrospinal fluid somatostatin levels affected by, 180
NMDA receptors
alcoholism and, 345
Norepinephrine–gamma-aminobutyric acid interactions
in limbic stress circuits, 166

Obsessive-compulsive disorder
anxiety associated with, 482
comorbidity-based subgroups of, 914
latent class analysis of, 914
Olfactory stimulus processing impairment
schizophrenia and, 403
Oligodendrocytes
superior frontal gyrus, in schizophrenia, 1075
Omega-3 fatty acids, 431
Orbital frontal cortex
depression and, in depressed elders, 144

Panic
doxapram model of, 863
drugs that induce symptoms of, 275
Paranoid schizophrenia
dihydropyrimidinase-related protein 2 gene on chromosome 8p21 and, 571
Pediatric bipolar disorder
adult bipolar disorder vs., 952
attention-deficit/hyperactivity disorder and, 952
behavior checklist for, 1036
behavioral inhibition and disinhibition as precursors to, 985
case studies of, 1043
clinical assessment of, 938
conduct disorder and, 952
description of, 931 (editorial)
diagnosis of, 938
evolution of, 945
family psychoeducation for, 1000
genetics of, 970
lithium for, 978
N-acetylaspartate levels in, 1059

parent advocacy perspective of, 935
parents with bipolar disorder, 945
pathophysiology of, 1009
pervasive manic symptoms in, 1050
pharmacotherapy for, 978
precursors to, 985
psychoeducation for, 1000
structured interviews for, 938
studies of, 1043, 1050
Systematic Treatment Enhancement Program for Bipolar Disorder, 1021
Perseveration behaviors
valproate effects on, in dopamine transporter knockdown mice, 352
Personality traits
dopamine D_2 receptor gene and, 577
Phenylalanine hydroxylase gene, 543
Positron emission tomography
cerebral function in posttraumatic stress disorder during verbal working memory updating, 474
Posttraumatic stress disorder. *See also* Trauma
acute reactions, 769
in adolescents
description of, 765, 809
treatment of, 827
animal model of, 463
childhood sexual abuse and, 879
in children
description of, 765, 809
treatment of, 827
cognitive behavioral therapy for, 817
early interventions for, 765 (editorial), 834
early predictors of, 789
emotional states in, 204
event-related potentials in, 216
mirtazapine for, 188
neural correlates of declarative memory for emotionally valenced words in women with, 879
population-based survey of, 769
predictors of, 789
psychological mechanisms in, 779
treatment of
early interventions, 765 (editorial), 834
mirtazapine, 188
pharmacological, 834
psychological interventions, 817
working memory updating in, cerebral function during, 474
Prefrontal cortex
amygdala responses to fearful stimuli modulated by, 494
attention-deficit/hyperactivity disorder, proton magnetic resonance spectroscopy evaluations of, 184
decision making in methamphetamine-dependent patients, 65
depression and, 39
dorsolateral, emotional self-regulation and, 502
inhibition, mediodorsal thalamic lesion effects on, 385
schizophrenia and
description of, 12, 376
white matter neurons, 39
selective serotonin reuptake inhibitor discontinuation effects on, 100
in Turner syndrome, 107
working memory deficits mediated by, 25
Prepotent response inhibition
in schizophrenia, 25
Prepulse inhibition
dopamine transporter and, 352
Proteomics, 847
Proton magnetic resonance spectroscopy
attention-deficit/hyperactivity disorder evaluations, 184
Psychoeducation, for pediatric bipolar disorder, 1000
Psychotic features, depression with, 680
Psychotropic drugs. *See also* Antipsychotic drugs
calcium/calmodulin dependent protein kinase II regulated by, 442

Rapid-cycling bipolar disorder
thyroid hypofunction in patients with, 899
Reboxetine
animal model of, 890
GABAergic neurons effect, 166
stress and, 890
Regional cerebral blood flow
clozapine effects, 601
in depression, 150
haloperidol effects, 601
Response inhibition
in schizophrenia, 25
in Turner syndrome, 107
Right lateral fusiform gyrus dysfunction
during facial information processing, in schizophrenia, 1099

Sadness
voluntary suppression of, neural circuitry associated with, 502
Schizoaffective disorder
essential polyunsaturated fatty acid levels in, 431
Schizophrenia
animal models of, 244
anterior cingulate cortex in, 1086
attentional dysfunctions in, 608
auditory gating in, 244
autoantibodies in, 361
brain development dysregulations in, 412
cannabis-sensitive dopaminergic markers in, 583
cerebellar asymmetry and
description of, 450
in Klinefelter's syndrome patient, 627
cerebrospinal fluid SNAP-25 levels in, 1133
chaos and, 3
classical conditioning in, 390
cognition in
atypical antipsychotic drugs effect on, 265–corr
elderly patients with
functional capacity in, 422
neuropsychological abilities, 422
essential polyunsaturated fatty acid levels in, 56, 431

executive dysfunctions in, 608
facial information processing in, right lateral fusiform gyrus dysfunction during, 1099
familial, hippocampal volume in, 555
first-episode
cerebellar asymmetry in, 450
hippocampal developmental abnormalities in, 555
gamma range activity in, visual masking as a probe for, 1114
GRIN1 gene and, 617
hippocampus in
developmental abnormalities, 555
recruitment of, 48
volume of, 562
Klinefelter's syndrome and, 627
lipid peroxide levels in, 56
memory performance, hippocampal recruitment in, 48
mismatch negativity generation deficits in, 1121
olfactory stimulus processing impairment in, 403
paranoid, dihydropyrimidinase-related protein 2 gene on chromosome 8p21 and, 571
perigenual cingulate gyrus volume in, 593
prefrontal cortex–posterior parietal networks in, 12
prepotent response inhibition in, 25
60 kDa autoantibodies in, 361
superior frontal gyrus in, oligodendrocytes of, 1075
superior temporal gyrus deficits of N-acetylaspartate and N-acetylaspartylglutamate in, 1133
thiobarbituric acid substances in, 56
working memory in
deficits, 12
endophenotype use of, 624
Seasonal affective disorder
catecholamine depletion and, 332
immunologic parameters in, 332
tryptophan depletion effects, 332
Seizure, alcohol-withdrawal
dopamine transporter gene in, 85
Selective serotonin reuptake inhibitors
cerebral blood volume changes after discontinuation of, 100
Selegiline
smoking cessation using, 136
Sensory gating
in hippocampus, 244
neuronal substrates of, 511
Serotonin
depression treated with, 193
neurotransmission, in generalized anxiety disorder, 304
Serum interleukin-2 receptor
in bipolar disorder, 157
Sexual abuse
posttraumatic stress disorder secondary to, 879
Signal transduction abnormalities
learned helplessness and, 520
Smoking
cessation using selegiline, 136
essential polyunsaturated fatty acids and, 431
maternal, conduct disturbance in boys and, 130
Somatostatin
cerebrospinal fluid levels of, in depression, 180
Stress
animal model of, 463
chronic, 292
reboxetine benefits for, 890
Stressors
behavioral and physical pathology secondary to, 292
Substance P
major depression and, 538
Superior frontal gyrus
oligodendrocytes of, in schizophrenia, 1075
Superior temporal cortex
N-acetylaspartate and N-acetylaspartylglutamate deficits in, in schizophrenia and bipolar disorder, 1139
Systematic Treatment Enhancement Program for Bipolar Disorder, 1021

T cells
in bipolar disorder, 157
Tactile perception
cortical excitability effects on, 175
Tardive dyskinesia, 1143
T-brain–1
in bipolar disorder, 39
Temperament, inhibited, 854
Terrorism, 765 (editorial)
Tetrahydrocannabinol
dopamine transporter affected by, in schizophrenia, 585
Thalamus
autism and, 121
emotional states in posttraumatic stress disorder and, 204
lesions of, effect on prefrontal cortical inhibition, 385
mediodorsal, 385
Thiobarbituric acid substances
in schizophrenia, 56
Thyroid hypofunction
rapid-cycling bipolar disorder in patients with, 899
Transcranial magnetic stimulation
cortical excitability with, 175
depression treated using, 324
repetitive, 324
Trauma. *See also* Posttraumatic stress disorder
acute reactions to
description of, 769
psychological mechanisms in, 779
in adolescents, 827
in children, 827
developmental psychobiology relevance to, 796
early interventions for, 765 (editorial), 817
population-based survey of reactions to, 769
psychological interventions for, 817
threat response and, 796
Tryptophan
seasonal affective disorder and, 332
Turner syndrome
executive dysfunction in, 107

prefrontal cortex in, 107
response inhibition in, 107

Visual event-related potentials
in posttraumatic stress disorder, 216
Visual masking
gamma range activity in schizophrenia assessed by, 1114
Voluntary suppression of emotional states, 502

White matter
schizophrenia-related dysregulations in, 412
Working memory
deficits of
prefrontal cortex mediation of, 25
schizophrenia and, 12, 376
schizophrenia and, 12, 376, 624
updating of, in posttraumatic stress disorder patients, 474